Stock of the Day

January 31, 2020

Abbott Laboratories (ABT)

$108.86
-$1.50 (-1.4%)
Market Cap: $190.97B

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Abbott Laboratories Bull Case

Here are some ways that investors could benefit from investing in Abbott Laboratories:

  • Abbott Laboratories recently reported strong second-quarter results on July 16, 2026, beating consensus estimates with earnings per share of $1.31 compared to the expected $1.28, while revenue of $12.59 billion also exceeded forecasts and grew 13.0% year-over-year, signaling robust operational momentum.
  • The stock is currently trading at $108.86, which is significantly below the average analyst price target of $118.17, suggesting that the market may be undervaluing the company relative to Wall Street's expectations for its future performance.
  • Wall Street maintains a "Moderate Buy" consensus rating for the stock, with recent upgrades from major firms like TD Cowen and BTIG Research in mid-2026 raising their price targets to $135.00 and $134.00 respectively, indicating growing institutional confidence in the company's trajectory.
  • Institutional investors are actively increasing their exposure to the company, with numerous new positions reported in the second quarter of 2026, including significant stakes from Meiji Yasuda Asset Management and Barrow Hanley Mewhinney & Strauss, reflecting broad-based demand from professional money managers.
  • Abbott Laboratories offers a stable income stream with a dividend yield of 2.24%, supported by a consistent payout history, which appeals to income-focused investors seeking regular cash returns alongside potential capital appreciation.

Abbott Laboratories Bear Case

Investors should be bearish about investing in Abbott Laboratories for these reasons:

  • The stock is trading at a price-to-earnings ratio of 35.23, which is relatively high and may limit upside potential if earnings growth does not accelerate to justify the premium valuation compared to historical averages.
  • Abbott Laboratories has a high dividend payout ratio of 81.55%, meaning the company is distributing a large portion of its earnings to shareholders, which could constrain its ability to reinvest in growth initiatives or absorb unexpected financial shocks.
  • The stock has experienced significant volatility recently, hitting a 52-week low of $81.97 in May 2026 before recovering, indicating that the market has been uncertain about the company's direction and that investors have faced substantial drawdowns in the past year.
  • Short interest in the stock has been notable, with over 20 million shares shorted in recent months, suggesting that a segment of the market is betting against the company's performance and that there is active bearish sentiment among traders.
  • Despite recent earnings beats, the company's full-year 2026 guidance of $5.45 to $5.60 per share is slightly below the consensus estimate of $5.48, which may indicate that management is cautious about sustaining the recent growth pace throughout the remainder of the fiscal year.
← Previous Stock of the DayNext Stock of the Day →

Recent News